462
Participants
Start Date
November 30, 2012
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
Standard Treatment
Standard treatment for Renal Cell Carcinoma
AGS-003
Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
New York
New York
Prague
New Hyde Park
Stony Brook
Albany
East Syracuse
Syracuse
Pittsburgh
Pittsburgh
Hershey
Danville
Easton
Prague
Allentown
Philadelphia
Philadelphia
Baltimore
Baltimore
Charlottesville
Virginia Beach
Winston-Salem
Raleigh
Durham
Madrid
Madrid
Madrid
Charlotte
Charleston
Myrtle Beach
Greenville
Marietta
Atlanta
Augusta
Haifa
Miami
Tampa
Vigo
Nashville
Seville
Toledo
Kfar Saba
Middletown
Cincinnati
Valencia
Liberec
Greenwood
Indianapolis
Indianapolis
Detroit
Detroit
Lansing
Grand Rapids
Hradec Králové
Iowa City
Tel Litwinsky
Milwaukee
Milwaukee
Minneapolis
Rochester
Sioux Falls
Maywood
Chicago
Springfield
St Louis
Kansas City
Wichita
Omaha
Omaha
Omaha
Metairie
New Orleans
New Orleans
Ẕerifin
Little Rock
Oklahoma City
Dallas
Rehovot
Houston
Olomouc
San Antonio
San Antonio
Aurora
Denver
Colorado Springs
Meridian
Boise
Salt Lake City
Scottsdale
Albuquerque
Los Angeles
Los Angeles
Jerusalem
La Jolla
San Francisco
Portland
Portland
Springfield
Seattle
Seattle
Boston
Burlington
Lebanon
Hackensack
Providence
Winnipeg
Hamilton
London
Oshawa
Ottawa
Greenfield Park
Montreal
Montreal
Québec
Budapest
Budapest
Debrecen
Roma
Rome
Badalona
Barcelona
Barcelona
Cambridge
Norwich
Preston
Lead Sponsor
Argos Therapeutics
INDUSTRY